What is the recommended first‑line pharmacologic and non‑pharmacologic management for an adult with chronic systolic heart failure (left ventricular ejection fraction ≤40%)?

Heart Failure Treatment: First-Line Management for Chronic Systolic Heart Failure (LVEF ≤40%)

All adults with chronic systolic heart failure (LVEF ≤40%) should be started on four foundational medication classes—ACE inhibitors (or ARB/ARNI), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors—initiated rapidly within 2-4 weeks, along with diuretics for fluid management and a supervised exercise-based cardiac rehabilitation program. 1, 2, 3

Pharmacologic Management: Rapid Sequencing Strategy

Step 1: Simultaneous Initiation (Week 1)

Start both a beta-blocker AND an SGLT2 inhibitor together on day one. 3

Beta-blocker selection and dosing:

• Use only one of the three proven beta-blockers: bisoprolol (start 1.25 mg daily, target 10 mg daily), carvedilol, or metoprolol succinate 1, 2
• Beta-blockers reduce mortality by 34%, the highest relative risk reduction among foundational therapies 1
• Initiate in a "start-low, go-slow" manner with monitoring of heart rate, blood pressure, and clinical status after each dose increase 4, 2
• Double the dose every 2 weeks if well tolerated 1
• Continue uptitration even if symptoms improve at lower doses, as clinical trials demonstrated benefits at target doses 1

SGLT2 inhibitor:

• Initiate simultaneously with beta-blocker as these drugs act independently and rapidly reduce morbidity and mortality 3
• SGLT2 inhibitors are now considered foundational therapy alongside traditional neurohormonal blockade 5, 3

Step 2: Add ACE Inhibitor or ARNI (Week 2-3)

Initiate sacubitril/valsartan (ARNI) or an ACE inhibitor 1-2 weeks after step 1. 3

• ACE inhibitors have a stronger evidence base than ARBs and should be preferred 2
• High-quality evidence shows ACE inhibitors reduce morbidity and increase survival 4
• Monitor renal function and electrolytes before initiation and 1-2 weeks after each dose adjustment 1, 2
• If ACE inhibitors are not tolerated due to intolerable adverse effects (not minor side effects), switch to an ARB 4, 2
• Patients intolerant of both ACE inhibitors and ARBs should receive combination hydralazine and nitrate therapy 4

Step 3: Add Mineralocorticoid Receptor Antagonist (Week 3-4)

Initiate an aldosterone antagonist (spironolactone or eplerenone) 1-2 weeks after step 2. 3

• Indicated when LVEF <35% and/or symptoms persist (NYHA class II-IV) 4
• Requires close monitoring of potassium levels and renal function 4, 2
• Check blood chemistry 1-2 weeks after initiation and after final dose titration 1

Diuretics for Fluid Management

Use loop diuretics to manage fluid retention and congestion. 2, 5

• Diuretics are essential for symptom control but do not prolong survival 4
• Advise daily weight monitoring and report weight gain >1.5-2.0 kg over 2 days 1

Non-Pharmacologic Management

Cardiac Rehabilitation

Offer a supervised group exercise-based rehabilitation program that includes psychological and educational components to all stable patients. 4

• Moderate-quality evidence shows exercise rehabilitation reduces hospital admissions and increases long-term quality of life 4
• Contraindicated only during acute decompensation or if patient has a device/condition precluding exercise 4

Lifestyle Modifications

Implement moderate sodium restriction, daily weight measurement, and encourage physical activity except during acute decompensation. 2

• Immunization with influenza and pneumococcal vaccines may reduce respiratory infection risk 2
• Close follow-up and patient education to detect early changes in weight or clinical status 2

Advanced Therapies for Persistent Symptoms

Cardiac Resynchronization Therapy (CRT)

Consider CRT for patients with LVEF <35% and QRS duration ≥150 ms, or 120-149 ms with mechanical dyssynchrony on echocardiography, who remain symptomatic despite optimal medical therapy. 4, 2

Implantable Cardioverter-Defibrillator (ICD)

Evaluate for ICD in patients with LVEF <35% who meet criteria: sustained ventricular tachycardia, nonsustained VT inducible on EP testing, or QRS ≥120 ms with LVEF <30%. 4

Critical Monitoring Requirements

Assess the following parameters:

• Heart rate, blood pressure, and clinical status after each medication titration 4, 1, 2
• Renal function and electrolytes before initiation and 1-2 weeks after each dose change 1, 2
• Volume status, orthostatic blood pressure, and weight at each visit 2
• Hold uptitration if heart rate <50 bpm, symptomatic hypotension, or signs of worsening heart failure 1

Common Pitfalls to Avoid

Do not underutilize beta-blockers in older adults (≥65 years), or in patients with peripheral vascular disease, erectile dysfunction, diabetes, interstitial pulmonary disease, or irreversible COPD. 4, 2

Do not stop uptitration when clinical improvement occurs—continue to target doses used in clinical trials. 1

Do not prematurely switch from ACE inhibitors to ARBs without an adequate trial demonstrating intolerable adverse effects. 2

Do not fail to monitor potassium and renal function closely when using ACE inhibitors, ARBs, or aldosterone antagonists together. 2

Do not delay initiation of all four foundational therapies—low starting doses have substantial therapeutic benefits, and achieving low doses of all four classes should take precedence over uptitration to target doses of individual agents. 3

Patient Education

Explain to patients that:

• Treatment prevents worsening of heart failure and increases survival 1
• Symptomatic improvement may develop slowly over 3-6 months 1
• Temporary symptomatic deterioration may occur in 20-30% during beta-blocker initiation 1
• Daily weight monitoring is essential 1

Rationale for Rapid Sequencing

The conventional approach requiring ≥6 months for medication initiation is not evidence-based and leads to major treatment gaps. 3

• Since drugs act rapidly to reduce morbidity and mortality, patients should start all four foundational treatments within 2-4 weeks 3
• The efficacy of each foundational therapy is independent of treatment with other drugs 3
• Low starting doses have substantial therapeutic benefits 3